ArticleOncology reports2019
LINC00461 affects the survival of patients with renal cell carcinoma by acting as a competing endogenous RNA for microRNA‑942.
Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- The role of SALL1-MGST1 axis-mediated ferroptosis inhibition in chemoresistance of retinoblastoma.PloS one · 2026Article
- Diagnostic Value and Mechanism of Action of LINC00641 in Sepsis-Associated Acute Kidney Injury.Journal of inflammation research · 2026Article
- Downregulation of SALL1 and its association with poor prognosis and the immune cell landscape in clear cell renal cell carcinoma.Frontiers in oncology · 2025Article
- Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Article
- A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment.Cancer cell international · 2023Review
- LncRNA LINC00461 exacerbates myocardial ischemia-reperfusion injury via microRNA-185-3p/Myd88.Molecular medicine (Cambridge, Mass.) · 2022Article
- The Prominent Role of miR-942 in Carcinogenesis of Tumors.Advanced biomedical research · 2022Review
- Identification of N6-Methyladenosine-Related lncRNAs as a Prognostic Signature in Glioma.Frontiers in oncology · 2022Article
- SALL Proteins; Common and Antagonistic Roles in Cancer.Cancers · 2021Review
- TF-RBP-AS Triplet Analysis Reveals the Mechanisms of Aberrant Alternative Splicing Events in Kidney Cancer: Implications for Their Possible Clinical Use as Prognostic and Therapeutic Biomarkers.International journal of molecular sciences · 2021Article
- LINC00461 facilitates HNSCC development and reduces chemosensitivity by impairing miR-195-mediated inhibition of HOXA10.Molecular therapy oncolytics · 2021Article
- Linc00641 promotes the progression of gastric carcinoma by modulating the miR-429/Notch-1 axis.Aging · 2021Article
- Identification of Prognostic Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma.Journal of oncology · 2021Article
- Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma.Frontiers in oncology · 2020Article
- Identification and Verification on Prognostic Index of Lower-Grade Glioma Immune-Related LncRNAs.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the potential mechanisms of human miR‑942 in the sunitinib‑resistance of renal cell carcinoma (RCC). A sunitinib‑resistant OS‑RC‑2 cell line was established by continuous exposure to increasing concentrations of sunitinib for ~12 weeks. The expression levels of four miRNAs were determined by reverse transcription‑quantitative (RT‑q)PCR. miR‑942 mimics were transfected into OS‑RC‑2 cells and RNA sequencing was performed on the miR‑942‑ and negative control‑transfected cells. Downregulated genes, including those of long non‑coding RNAs (lncRNAs) and mRNAs, were identified. The target genes of miR‑942 were predicted, followed by protein‑protein interaction network construction and functional enrichment analyses of miR‑942 target genes. In addition, RCC RNA‑seq and miRNA‑seq data were downloaded from The Cancer Genome Atlas (TCGA) database. The contributions of lncRNA and/or mRNAs to survival prediction were assessed and a competing endogenous RNA (ceRNA) network consisting of miR‑942, lncRNA and mRNAs was constructed. The expression levels of LINC00461, miR‑942, spalt‑like transcription factor 1 (SALL1), methionyl aminopeptidase 1 (METAP1) and DDB1 and CUL4 associated factor 1 (DCAF11) were verified using RT‑qPCR. The role of LINC00461 in cell viability was detected by MTT assay. The expression level of miR‑942 was significantly increased in sunitinib‑resistant cells. A total of seven lncRNAs and 155 mRNAs were predicted as target genes of miR‑942 in the miR‑942 mimic‑treated samples, compared with the mimic control‑treated group. These potential target genes were significantly associated with 'protein binding', 'TNF‑β signaling pathway', 'negative transcriptional regulation' and 'RNA binding'. Through the integrated analysis of RNA‑sequencing and TCGA data, an miR‑942‑related ceRNA network, which was predicted to significantly affect the survival of patients with RCC, was constructed. The expression levels of lncRNA LINC00461 and the genes SALL1, METAP1, and DCAF11 were further verified. The viability of OS‑RC‑2 cells was decreased following co‑transfection with miR‑942 mimics and LINC00641 siRNA, and was comparable to that of wild type OS‑RC‑2 cells (P>0.05). Therefore, lncRNA LINC00461 may act as an miR‑942 ceRNA, and affect the survival of patients with RCC by regulating the expression of SALL1, METAP1 and DCAF11.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.